Vaccine adverse reactions, what emerges from the latest Aifa report
Here are numbers and details on the adverse reactions to anti-Covid vaccines contained in the eighth pharmacovigilance report released by Aifa
Between December 27, 2020, the day of the start of the anti-Covid vaccination campaign, and last August 26, the National Pharmacovigilance Network received 91,360 reports of suspected adverse reaction to anti-Covid vaccines out of a total of 76,509,846 doses administered.
Here are all the details that emerge from the eighth Pharmacovigilance Report on Covid-19 vaccines released by the Italian drug agency Aifa.
THE REPORTING RATE
The reporting rate is 119 per 100 thousand doses, and of the total reported effects 86.1% refers to non-serious events such as pain at the injection site, fever, asthenia / fatigue, muscle aches. Serious reports correspond to 13.8% of the total with a rate equal to 13 serious events per 100 thousand vaccine doses administered.
REACTION ON THE SAME DAY OF VACCINATION
As reported in the previous reports – reads the eighth report – regardless of the vaccine, the dose and the type of event, the reaction occurred in most cases (about 80%) on the same day of vaccination or the next day, and only more rarely beyond the following 48 hours.
WHICH ARE THE MOST USED VACCINES
Comirnaty (Pfizer / BioNTech) – highlights Aifa – is the vaccine currently most used in the Italian vaccination campaign (71%), followed by Vaxzevria from AstraZeneca (16%), Spikevax from Moderna (11%) and Janssen from Johnson & Johnson (2%).
SIDE EFFECTS AND TYPES OF VACCINE
And in line with previous reports, the distribution of reports of suspected adverse events by type of vaccine is similar to that of administrations: Comirnaty 67%, Vaxzevria 24%, Spikevax 8%, Janssen 1%. For all vaccines, the most reported adverse events are fever, fatigue, headache, muscle / joint pain, local reaction or pain at the injection site, chills and nausea.
THE DATA OF THE UNDER 60
In relation to the so-called heterologous vaccinations to people under 60 who had received Vaxzevria (AstraZeneca) as their first anti-Covid dose, up to 26 August the National Pharmacovigilance Network received 248 reports of suspected adverse events, out of a total of 604,865 administrations, with a reporting rate of 41 for every 100,000 doses administered. The second dose concerned Comirnaty (Pfizer / BioNTech) in 76% of cases and Spikevax (Moderna) in 24%.
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/rapporto-aifa-vaccini-reazioni-avverse/ on Sat, 11 Sep 2021 06:08:50 +0000.